Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FARESTON vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, exerting antiestrogenic effects in breast tissue.
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
FDA-approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors,Off-label: treatment of advanced breast cancer in premenopausal women in combination with ovarian suppression
Moderate to severe pain relief; combinations are used to reduce abuse potential.
60 mg orally once daily.
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
The terminal elimination half-life of toremifene is approximately 5 days (range 2-10 days). The half-life of its main metabolite, N-desmethyltoremifene, is about 11 days. This long half-life supports once-daily dosing.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
Primarily hepatic via CYP3A4 and CYP1A2; undergoes glucuronidation; active metabolite N-desmethyltoremifene
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
FARESTON (toremifene) is extensively metabolized in the liver. Excretion is primarily fecal (approximately 70%) with renal excretion accounting for less than 10% of the dose as unchanged drug and metabolites.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Toremifene is >99% bound to plasma proteins, primarily albumin.
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
The apparent volume of distribution (Vd) is approximately 580 L (about 8 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
Oral bioavailability of toremifene is not precisely determined but is estimated to be nearly 100% based on absorption and first-pass metabolism studies.
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
No dose adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
Contraindicated in Child-Pugh class C; use with caution in class A or B without specific dose reduction guidelines.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
Safety and efficacy not established; no recommended dose.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
No specific dose adjustment; monitor renal function and electrolyte balance.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
None
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
QT interval prolongation,Hypercalcemia in patients with bone metastases,Endometrial hyperplasia/cancer risk,Thromboembolic events,Ocular toxicity (dose-dependent retinopathy),Tumor flare
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Hypersensitivity to toremifene or any excipients,History of thromboembolic disease,Pre-existing endometrial hyperplasia,Patients with long QT syndrome or concurrent use of QT-prolonging drugs
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition, which can increase toremifene levels and risk of adverse effects. No other significant food interactions known. Take with or without food.
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
Pregnancy Category D. First trimester: Risk of fetal harm, including spontaneous abortion and congenital malformations (e.g., craniofacial, cardiac). Second and third trimesters: Potential for fetal hypothalamic-pituitary-gonadal axis disruption, ambiguous genitalia in female fetuses, and other adverse effects based on animal studies.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
Not recommended during breastfeeding. Toremifene may be excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants, including hormonal disruption.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
No established dose adjustments; use contraindicated in pregnancy. Pharmacokinetic changes (increased volume of distribution, altered clearance) may require empirical dose reduction if used inadvertently, but no specific guidelines exist. Avoid use.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
FARESTON (toremifene) is a selective estrogen receptor modulator (SERM) used for metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors. Unlike tamoxifen, toremifene has a longer half-life (about 5 days) and may have a lower risk of thromboembolic events. Monitor liver function tests regularly due to potential hepatotoxicity. Prolongation of QT interval has been reported; avoid in patients with pre-existing QTc prolongation or with other QT-prolonging drugs. Use with caution in patients with endometrial hyperplasia or history of thromboembolic disease.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Take this medication exactly as prescribed, usually once daily with or without food.,You may experience hot flashes, nausea, or sweating; these are common and usually manageable.,Report any unusual vaginal bleeding, discharge, or pelvic pain to your doctor immediately.,Watch for signs of blood clots such as leg pain/swelling, sudden chest pain, or shortness of breath.,Avoid grapefruit and grapefruit juice while on this medication as they may increase side effects.,Use non-hormonal contraception if you are still able to become pregnant; toremifene can harm a fetus.,Do not stop or change your dose without consulting your healthcare provider.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
No interactions on record
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FARESTON vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
FARESTON is a Selective Estrogen Receptor Modulator that works by Selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, exerting antiestrogenic effects in breast tissue.. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FARESTON and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FARESTON is: 60 mg orally once daily.. The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FARESTON and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FARESTON is classified as Category C. Pregnancy Category D. First trimester: Risk of fetal harm, including spontaneous abortion and congenital malformations (e.g., craniofacial, cardiac). Second and third trimesters: P. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.